Is SGMT or VERA more profitable?

Sagimet Biosciences' return on equity of -31.96% beat Vera Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Sagimet Biosciences N/A -31.96% -30.57% Vera Therapeutics N/A -84.13% -66.79%

Does the media favor SGMT or VERA?

In the previous week, Sagimet Biosciences had 13 more articles in the media than Vera Therapeutics. MarketBeat recorded 20 mentions for Sagimet Biosciences and 7 mentions for Vera Therapeutics. Sagimet Biosciences' average media sentiment score of 0.43 beat Vera Therapeutics' score of 0.16 indicating that Sagimet Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sagimet Biosciences 4 Very Positive mention(s) 4 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Vera Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor SGMT or AUPH?

In the previous week, Sagimet Biosciences had 18 more articles in the media than Aurinia Pharmaceuticals. MarketBeat recorded 20 mentions for Sagimet Biosciences and 2 mentions for Aurinia Pharmaceuticals. Sagimet Biosciences' average media sentiment score of 0.43 beat Aurinia Pharmaceuticals' score of 0.30 indicating that Sagimet Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sagimet Biosciences 4 Very Positive mention(s) 4 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Aurinia Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to VCEL or SGMT?

In the previous week, Sagimet Biosciences had 17 more articles in the media than Vericel. MarketBeat recorded 20 mentions for Sagimet Biosciences and 3 mentions for Vericel. Vericel's average media sentiment score of 0.99 beat Sagimet Biosciences' score of 0.43 indicating that Vericel is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vericel 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Sagimet Biosciences 4 Very Positive mention(s) 4 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor SGMT or VRDN?

In the previous week, Sagimet Biosciences had 16 more articles in the media than Viridian Therapeutics. MarketBeat recorded 20 mentions for Sagimet Biosciences and 4 mentions for Viridian Therapeutics. Viridian Therapeutics' average media sentiment score of 0.52 beat Sagimet Biosciences' score of 0.43 indicating that Viridian Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sagimet Biosciences 4 Very Positive mention(s) 4 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Viridian Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer SGMT or BCRX?

In the previous week, Sagimet Biosciences had 16 more articles in the media than BioCryst Pharmaceuticals. MarketBeat recorded 20 mentions for Sagimet Biosciences and 4 mentions for BioCryst Pharmaceuticals. Sagimet Biosciences' average media sentiment score of 0.43 beat BioCryst Pharmaceuticals' score of 0.23 indicating that Sagimet Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sagimet Biosciences 4 Very Positive mention(s) 4 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral BioCryst Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Sagimet Biosciences (SGMT) Competitors

$8.92 +0.04 (+0.45%)

Closing price 10/8/2026 04:00 PM Eastern

Extended Trading

$8.84 -0.08 (-0.94%)

As of 04:08 AM Eastern

Compare

SGMT vs. VERA, AUPH, VCEL, VRDN, and BCRX

Should you buy Sagimet Biosciences stock or one of its competitors? Sagimet Biosciences's main competitors and comparable companies include Vera Therapeutics (VERA), Aurinia Pharmaceuticals (AUPH), Vericel (VCEL), Viridian Therapeutics (VRDN), and BioCryst Pharmaceuticals (BCRX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Sagimet Biosciences compare to Vera Therapeutics?

Sagimet Biosciences (NASDAQ:SGMT) and Vera Therapeutics (NASDAQ:VERA) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, risk, earnings, profitability, media sentiment, institutional ownership, dividends and analyst recommendations.

87.9% of Sagimet Biosciences shares are owned by institutional investors. Comparatively, 99.2% of Vera Therapeutics shares are owned by institutional investors. 11.5% of Sagimet Biosciences shares are owned by insiders. Comparatively, 15.9% of Vera Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Sagimet Biosciences currently has a consensus price target of $26.63, suggesting a potential upside of 198.59%. Vera Therapeutics has a consensus price target of $80.15, suggesting a potential upside of 169.61%. Given Sagimet Biosciences' higher probable upside, equities analysts clearly believe Sagimet Biosciences is more favorable than Vera Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sagimet Biosciences	2 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.58
Vera Therapeutics	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.86

Sagimet Biosciences' return on equity of -31.96% beat Vera Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sagimet Biosciences	N/A	-31.96%	-30.57%
Vera Therapeutics	N/A	-84.13%	-66.79%

In the previous week, Sagimet Biosciences had 13 more articles in the media than Vera Therapeutics. MarketBeat recorded 20 mentions for Sagimet Biosciences and 7 mentions for Vera Therapeutics. Sagimet Biosciences' average media sentiment score of 0.43 beat Vera Therapeutics' score of 0.16 indicating that Sagimet Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sagimet Biosciences	4 Very Positive mention(s)	4 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Vera Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Sagimet Biosciences has higher revenue and earnings than Vera Therapeutics. Sagimet Biosciences is trading at a lower price-to-earnings ratio than Vera Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sagimet Biosciences	$2M	277.23	-$51.04M	-$1.28	N/A
Vera Therapeutics	N/A	N/A	-$299.61M	-$5.86	N/A

Sagimet Biosciences has a beta of 3.46, suggesting that its share price is 246% more volatile than the broader market. Comparatively, Vera Therapeutics has a beta of 1.06, suggesting that its share price is 6% more volatile than the broader market.

Summary

Sagimet Biosciences beats Vera Therapeutics on 9 of the 15 factors compared between the two stocks.

How does Sagimet Biosciences compare to Aurinia Pharmaceuticals?

Sagimet Biosciences (NASDAQ:SGMT) and Aurinia Pharmaceuticals (NASDAQ:AUPH) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, valuation, profitability, media sentiment, analyst recommendations, earnings, institutional ownership and dividends.

Sagimet Biosciences has a beta of 3.46, meaning that its stock price is 246% more volatile than the broader market. Comparatively, Aurinia Pharmaceuticals has a beta of 1.6, meaning that its stock price is 60% more volatile than the broader market.

Sagimet Biosciences currently has a consensus target price of $26.63, suggesting a potential upside of 198.59%. Aurinia Pharmaceuticals has a consensus target price of $17.67, suggesting a potential upside of 8.92%. Given Sagimet Biosciences' higher possible upside, equities research analysts clearly believe Sagimet Biosciences is more favorable than Aurinia Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sagimet Biosciences	2 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.58
Aurinia Pharmaceuticals	0 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.67

Aurinia Pharmaceuticals has a net margin of 100.84% compared to Sagimet Biosciences' net margin of 0.00%. Aurinia Pharmaceuticals' return on equity of 26.11% beat Sagimet Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sagimet Biosciences	N/A	-31.96%	-30.57%
Aurinia Pharmaceuticals	100.84%	26.11%	19.89%

87.9% of Sagimet Biosciences shares are owned by institutional investors. Comparatively, 36.8% of Aurinia Pharmaceuticals shares are owned by institutional investors. 11.5% of Sagimet Biosciences shares are owned by company insiders. Comparatively, 10.4% of Aurinia Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

In the previous week, Sagimet Biosciences had 18 more articles in the media than Aurinia Pharmaceuticals. MarketBeat recorded 20 mentions for Sagimet Biosciences and 2 mentions for Aurinia Pharmaceuticals. Sagimet Biosciences' average media sentiment score of 0.43 beat Aurinia Pharmaceuticals' score of 0.30 indicating that Sagimet Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sagimet Biosciences	4 Very Positive mention(s)	4 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Aurinia Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Aurinia Pharmaceuticals has higher revenue and earnings than Sagimet Biosciences. Sagimet Biosciences is trading at a lower price-to-earnings ratio than Aurinia Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sagimet Biosciences	$2M	277.23	-$51.04M	-$1.28	N/A
Aurinia Pharmaceuticals	$283.05M	7.62	$287.20M	$2.29	7.08

Summary

Aurinia Pharmaceuticals beats Sagimet Biosciences on 9 of the 17 factors compared between the two stocks.

How does Sagimet Biosciences compare to Vericel?

Vericel (NASDAQ:VCEL) and Sagimet Biosciences (NASDAQ:SGMT) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, media sentiment, valuation, institutional ownership, earnings, profitability, risk and analyst recommendations.

Vericel has higher revenue and earnings than Sagimet Biosciences. Sagimet Biosciences is trading at a lower price-to-earnings ratio than Vericel, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vericel	$276.26M	7.42	$16.52M	$0.47	85.21
Sagimet Biosciences	$2M	277.23	-$51.04M	-$1.28	N/A

87.9% of Sagimet Biosciences shares are held by institutional investors. 7.6% of Vericel shares are held by insiders. Comparatively, 11.5% of Sagimet Biosciences shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Vericel has a net margin of 7.91% compared to Sagimet Biosciences' net margin of 0.00%. Vericel's return on equity of 6.91% beat Sagimet Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vericel	7.91%	6.91%	5.02%
Sagimet Biosciences	N/A	-31.96%	-30.57%

Vericel currently has a consensus target price of $58.40, indicating a potential upside of 45.82%. Sagimet Biosciences has a consensus target price of $26.63, indicating a potential upside of 198.59%. Given Sagimet Biosciences' higher possible upside, analysts plainly believe Sagimet Biosciences is more favorable than Vericel.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vericel	0 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.67
Sagimet Biosciences	2 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.58

In the previous week, Sagimet Biosciences had 17 more articles in the media than Vericel. MarketBeat recorded 20 mentions for Sagimet Biosciences and 3 mentions for Vericel. Vericel's average media sentiment score of 0.99 beat Sagimet Biosciences' score of 0.43 indicating that Vericel is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vericel	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Sagimet Biosciences	4 Very Positive mention(s)	4 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Vericel has a beta of 1.02, suggesting that its share price is 2% more volatile than the broader market. Comparatively, Sagimet Biosciences has a beta of 3.46, suggesting that its share price is 246% more volatile than the broader market.

Summary

Vericel beats Sagimet Biosciences on 9 of the 16 factors compared between the two stocks.

How does Sagimet Biosciences compare to Viridian Therapeutics?

Sagimet Biosciences (NASDAQ:SGMT) and Viridian Therapeutics (NASDAQ:VRDN) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, risk, institutional ownership, valuation, dividends, earnings, profitability and media sentiment.

Sagimet Biosciences has a beta of 3.46, indicating that its share price is 246% more volatile than the broader market. Comparatively, Viridian Therapeutics has a beta of 1.11, indicating that its share price is 11% more volatile than the broader market.

Sagimet Biosciences has a net margin of 0.00% compared to Viridian Therapeutics' net margin of -505.86%. Sagimet Biosciences' return on equity of -31.96% beat Viridian Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sagimet Biosciences	N/A	-31.96%	-30.57%
Viridian Therapeutics	-505.86%	-72.97%	-42.80%

In the previous week, Sagimet Biosciences had 16 more articles in the media than Viridian Therapeutics. MarketBeat recorded 20 mentions for Sagimet Biosciences and 4 mentions for Viridian Therapeutics. Viridian Therapeutics' average media sentiment score of 0.52 beat Sagimet Biosciences' score of 0.43 indicating that Viridian Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sagimet Biosciences	4 Very Positive mention(s)	4 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Viridian Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Sagimet Biosciences has higher earnings, but lower revenue than Viridian Therapeutics. Sagimet Biosciences is trading at a lower price-to-earnings ratio than Viridian Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sagimet Biosciences	$2M	277.23	-$51.04M	-$1.28	N/A
Viridian Therapeutics	$70.85M	29.33	-$342.60M	-$3.37	N/A

87.9% of Sagimet Biosciences shares are held by institutional investors. 11.5% of Sagimet Biosciences shares are held by insiders. Comparatively, 2.4% of Viridian Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Sagimet Biosciences presently has a consensus target price of $26.63, indicating a potential upside of 198.59%. Viridian Therapeutics has a consensus target price of $38.69, indicating a potential upside of 110.97%. Given Sagimet Biosciences' higher possible upside, equities analysts clearly believe Sagimet Biosciences is more favorable than Viridian Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sagimet Biosciences	2 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.58
Viridian Therapeutics	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.85

Summary

Sagimet Biosciences beats Viridian Therapeutics on 11 of the 16 factors compared between the two stocks.

How does Sagimet Biosciences compare to BioCryst Pharmaceuticals?

Sagimet Biosciences (NASDAQ:SGMT) and BioCryst Pharmaceuticals (NASDAQ:BCRX) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, valuation, institutional ownership, risk, profitability, earnings, media sentiment and analyst recommendations.

Sagimet Biosciences has a net margin of 0.00% compared to BioCryst Pharmaceuticals' net margin of -40.90%. Sagimet Biosciences' return on equity of -31.96% beat BioCryst Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sagimet Biosciences	N/A	-31.96%	-30.57%
BioCryst Pharmaceuticals	-40.90%	-86.89%	66.37%

87.9% of Sagimet Biosciences shares are owned by institutional investors. Comparatively, 85.9% of BioCryst Pharmaceuticals shares are owned by institutional investors. 11.5% of Sagimet Biosciences shares are owned by insiders. Comparatively, 3.8% of BioCryst Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Sagimet Biosciences has a beta of 3.46, suggesting that its share price is 246% more volatile than the broader market. Comparatively, BioCryst Pharmaceuticals has a beta of 0.55, suggesting that its share price is 45% less volatile than the broader market.

BioCryst Pharmaceuticals has higher revenue and earnings than Sagimet Biosciences. Sagimet Biosciences is trading at a lower price-to-earnings ratio than BioCryst Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sagimet Biosciences	$2M	277.23	-$51.04M	-$1.28	N/A
BioCryst Pharmaceuticals	$874.84M	2.42	$263.86M	-$1.50	N/A

Sagimet Biosciences presently has a consensus price target of $26.63, indicating a potential upside of 198.59%. BioCryst Pharmaceuticals has a consensus price target of $20.50, indicating a potential upside of 147.29%. Given Sagimet Biosciences' stronger consensus rating and higher possible upside, analysts plainly believe Sagimet Biosciences is more favorable than BioCryst Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sagimet Biosciences	2 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.58
BioCryst Pharmaceuticals	1 Sell rating(s)	4 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.50

In the previous week, Sagimet Biosciences had 16 more articles in the media than BioCryst Pharmaceuticals. MarketBeat recorded 20 mentions for Sagimet Biosciences and 4 mentions for BioCryst Pharmaceuticals. Sagimet Biosciences' average media sentiment score of 0.43 beat BioCryst Pharmaceuticals' score of 0.23 indicating that Sagimet Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sagimet Biosciences	4 Very Positive mention(s)	4 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
BioCryst Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Sagimet Biosciences beats BioCryst Pharmaceuticals on 12 of the 16 factors compared between the two stocks.

Get Sagimet Biosciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SGMT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SGMT vs. The Competition

Export

Metric	Sagimet Biosciences	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$551.97M	$3.87B	$7.20B	$13.40B
Dividend Yield	N/A	3.65%	2.53%	16.36%
P/E Ratio	-6.97	13.89	274.66	25.98
Price / Sales	N/A	1,216.17	588.74	88.53
Price / Cash	N/A	117.60	76.82	53.72
Price / Book	2.61	16.28	10.88	6.27
Net Income	-$51.04M	-$22.69M	$3.50B	$382.01M
7 Day Performance	-2.41%	-2.88%	-1.83%	-1.60%
1 Month Performance	-17.86%	-11.16%	-6.34%	-4.63%
1 Year Performance	3.48%	8.30%	3.08%	-0.95%

Sagimet Biosciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SGMT Sagimet Biosciences	2.7989 of 5 stars	$8.92 +0.5%	$26.63 +198.6%	+22.0%	$551.97M	N/A	N/A	16	Analyst Revision
VERA Vera Therapeutics	3.9339 of 5 stars	$28.95 -2.9%	$80.15 +176.9%	-2.5%	$2.09B	N/A	N/A	361
AUPH Aurinia Pharmaceuticals	2.7666 of 5 stars	$15.62 -0.7%	$17.67 +13.1%	+40.7%	$2.08B	$283.05M	6.82	128	News Coverage
VCEL Vericel	3.5902 of 5 stars	$40.06 -2.5%	$58.40 +45.8%	+17.3%	$2.05B	$276.26M	85.34	398
VRDN Viridian Therapeutics	2.5472 of 5 stars	$18.12 -4.6%	$38.69 +113.6%	-14.1%	$2.05B	$71.13M	N/A	252

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SGMT) was last updated on 10/9/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Sagimet Biosciences (SGMT) Competitors

SGMT vs. VERA, AUPH, VCEL, VRDN, and BCRX

How does Sagimet Biosciences compare to Vera Therapeutics?

Summary

How does Sagimet Biosciences compare to Aurinia Pharmaceuticals?

Summary

How does Sagimet Biosciences compare to Vericel?

Summary

How does Sagimet Biosciences compare to Viridian Therapeutics?

Summary

How does Sagimet Biosciences compare to BioCryst Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SGMT vs. The Competition

Sagimet Biosciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Sagimet Biosciences (SGMT) Competitors

SGMT vs. VERA, AUPH, VCEL, VRDN, and BCRX

How does Sagimet Biosciences compare to Vera Therapeutics?

Do insiders and institutionals hold more shares of SGMT or VERA?

Do analysts rate SGMT or VERA?

Is SGMT or VERA more profitable?

Does the media favor SGMT or VERA?

Which has preferable earnings & valuation, SGMT or VERA?

Which has more volatility and risk, SGMT or VERA?

Summary

How does Sagimet Biosciences compare to Aurinia Pharmaceuticals?

Which has more volatility & risk, SGMT or AUPH?

Do analysts prefer SGMT or AUPH?

Is SGMT or AUPH more profitable?

Do institutionals & insiders hold more shares of SGMT or AUPH?

Does the media favor SGMT or AUPH?

Which has higher valuation & earnings, SGMT or AUPH?

Summary

How does Sagimet Biosciences compare to Vericel?

Which has higher earnings & valuation, VCEL or SGMT?

Do insiders and institutionals believe in VCEL or SGMT?

Is VCEL or SGMT more profitable?

Do analysts prefer VCEL or SGMT?

Does the media refer more to VCEL or SGMT?

Which has more volatility and risk, VCEL or SGMT?

Summary

How does Sagimet Biosciences compare to Viridian Therapeutics?

Which has more risk and volatility, SGMT or VRDN?

Is SGMT or VRDN more profitable?

Does the media favor SGMT or VRDN?

Which has higher valuation and earnings, SGMT or VRDN?

Do institutionals and insiders believe in SGMT or VRDN?

Do analysts prefer SGMT or VRDN?

Summary

How does Sagimet Biosciences compare to BioCryst Pharmaceuticals?

Is SGMT or BCRX more profitable?

Do institutionals & insiders believe in SGMT or BCRX?

Which has more risk & volatility, SGMT or BCRX?

Which has better earnings & valuation, SGMT or BCRX?

Do analysts prefer SGMT or BCRX?

Does the media prefer SGMT or BCRX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SGMT vs. The Competition

Sagimet Biosciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools